RIMAG GROUP(02522): YINGHEYIMAI releases the world's first pedestal large model-driven AI-assisted diagnostic product.

RIMAG GROUP (02522) announced that on October 16, 2025, Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. (Yinghe Yimai), a joint venture incubated by the group, officially launched the world's first AI-assisted diagnostic product based on the medical imaging base model "Yinghe Mige" developed by AIR (Pathology-level AI Assisted Diagnosis Product) - Chest CT Plain Scan Assisted Diagnosis. AIR. The AIR product marks the official transition of medical imaging AI from the "single disease small model" 1.0 era to the "base large model-driven" 2.0 era, with the ability to diagnose all lesions, all diseases, and multiple organs synergistically. It is a milestone breakthrough in the field of intelligent medical imaging diagnosis. The AIR product uses the scanned area as the diagnostic unit, with the first landing product focusing on chest CT plain scan, achieving simultaneous detection and diagnosis of all lesions of the lungs, pleura, mediastinum, and other organs with one scan, covering all common diseases in that area. The AIR product is developed based on the world's first cross-modal, full-process medical imaging base model "Yinghe Mige", with the ability for multi-organ linkage segmentation, fully demonstrating its technical advantages of efficient diagnosis, precise coverage, interactive collaboration, and seamless integration, fundamentally reconstructing the research and application logic of medical imaging AI. The AIR product is not only a diagnostic tool, but also the first commercialized result of the Yinghe Yimai base model ecosystem. By connecting top hospitals with grassroots medical institutions through open interfaces, it forms a positive cycle of "data feedback model iteration, model driving scene landing." This model will significantly shorten the AI product development cycle, reduce development costs, help medical institutions standardize screening, intelligent diagnosis, and universalize services, effectively promote industry chain collaboration, and build a closed-loop ecosystem of "data-model-scene." The release of the AIR product marks the transition of medical imaging AI from "single-point breakthroughs" to "systematic empowerment", upgrading from "tool assistance" to "diagnostic partner". Its diagnostic logic centered on examination items is more in line with the actual clinical reading process, promoting the industry from "single disease detection" to "collaborative analysis of all diseases", providing a new paradigm for health screening, precise diagnosis and treatment, and remote medical care scenarios. The technological innovation of the AIR product "simultaneous diagnosis of multiple diseases with one scan" can significantly enhance the competitiveness and added value of the group's imaging center services. The group will synergize its resource advantages in medical imaging data and scenarios with Yinghe Yimai, continuously optimize the performance of the base large model, expand AI diagnostic products for more examination items, and work with industry partners to collectively promote the "efficiency revolution" of medical imaging AI, making intelligent diagnosis more accurate, faster, and more accessible.